Details of the Drug

General Information of Drug (ID: DMA6S1D)

Drug Name

Ropinirole

Synonyms

Ropinirol; Ropinirolum; Ropitor; ReQuip CR; ReQuip XL; SKF 101468; Adartrel (TN); Requip (TN); Ropark (TN); Ropinirol[INN-Spanish]; Ropinirole (INN); Ropinirole [INN:BAN]; Ropinirolum [INN-Latin]; Ropitor (TN); SK&F 101468; SK&F-101,468; 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(Dipropylamino)ethyl]indoline-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antiparkinson Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

260.37

Logarithm of the Partition Coefficient (xlogp)

2.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 3.1234 micromolh/L [2]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 0.0109 micromol/L [2]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 56 h [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 89% [2]
Clearance: The clearance of drug is 47 L/h []
Elimination: The majority of the absorbed dose is cleared by the liver, and more than 88% of a radiolabeled dose was recovered in urine [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 6 hours [5]
Metabolism: The drug is metabolized via the liver [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.3168 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.6% [7]
Vd: The volume of distribution (Vd) of drug is 7.5 L/kg []
Water Solubility: The ability of drug to dissolve in water is measured as 133 mg/mL [3]

Chemical Identifiers

Formula: C16H24N2O
IUPAC Name: 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
Canonical SMILES: CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
InChI: InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)
InChIKey: UHSKFQJFRQCDBE-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5095
ChEBI ID: CHEBI:8888
CAS Number: 91374-21-9
DrugBank ID: DB00268
TTD ID: D0R9EQ
INTEDE ID: DR1440
ACDINA ID: D00606

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Modulator	[8]
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Modulator	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[11]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Post-Translational Modifications	[11]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Post-Translational Modifications	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Parkinson disease

ICD Disease Classification

8A00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	7.36E-01	1.62E-02	1.08E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ropinirole (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Memantine	DMD9WSC	Minor	Additive dopaminergic effects by the combination of Ropinirole and Memantine.	Alzheimer disease [8A20]	[12]
Promazine	DMZAL7W	Moderate	Antagonize the effect of Ropinirole when combined with Promazine.	Appearance/behaviour symptom [MB23]	[13]
Obeticholic acid	DM3Q1SM	Moderate	Decreased metabolism of Ropinirole caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[14]
Ciprofloxacin XR	DM2NLS9	Moderate	Decreased metabolism of Ropinirole caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Norfloxacin	DMIZ6W2	Moderate	Decreased metabolism of Ropinirole caused by Norfloxacin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Grepafloxacin	DMGLX0T	Moderate	Decreased metabolism of Ropinirole caused by Grepafloxacin mediated inhibition of CYP450 enzyme.	Bronchitis [CA20]	[14]
Niclosamide	DMJAGXQ	Moderate	Decreased metabolism of Ropinirole caused by Niclosamide mediated inhibition of CYP450 enzyme.	Cestodes infection [1F70-1F76]	[14]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Ropinirole and Olopatadine.	Conjunctiva disorder [9A60]	[15]
Ropivacaine	DMSPJG2	Minor	Increased plasma concentrations of Ropinirole and Ropivacaine due to competitive inhibition of the same metabolic pathway.	Corneal disease [9A76-9A78]	[16]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Ropinirole caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[14]
OPC-34712	DMHG57U	Moderate	Antagonize the effect of Ropinirole when combined with OPC-34712.	Depression [6A70-6A7Z]	[13]
Amoxapine	DMKITQE	Moderate	Antagonize the effect of Ropinirole when combined with Amoxapine.	Depression [6A70-6A7Z]	[13]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Ropinirole and Esketamine.	Depression [6A70-6A7Z]	[17]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Ropinirole and Brimonidine.	Glaucoma [9C61]	[18]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Ropinirole caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[14]
Teriflunomide	DMQ2FKJ	Moderate	Increased metabolism of Ropinirole caused by Teriflunomide mediated induction of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[17]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Ropinirole caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[14]
Propiomazine	DMKY8V1	Moderate	Antagonize the effect of Ropinirole when combined with Propiomazine.	Insomnia [7A00-7A0Z]	[13]
ITI-007	DMUQ1DO	Moderate	Antagonize the effect of Ropinirole when combined with ITI-007.	Insomnia [7A00-7A0Z]	[13]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Ropinirole caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[19]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Ropinirole caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[14]
Primaquine	DMWQ16I	Moderate	Decreased metabolism of Ropinirole caused by Primaquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[14]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Ropinirole caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[20]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Ropinirole and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[21]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Ropinirole and Lasmiditan.	Migraine [8A80]	[22]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Ropinirole caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[23]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Ropinirole and Flibanserin.	Mood disorder [6A60-6E23]	[24]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Ropinirole and Thalidomide.	Multiple myeloma [2A83]	[25]
Droperidol	DM0DXA8	Moderate	Antagonize the effect of Ropinirole when combined with Droperidol.	Nausea/vomiting [MD90]	[13]
Prochlorperazine	DM53SRA	Moderate	Antagonize the effect of Ropinirole when combined with Prochlorperazine.	Nausea/vomiting [MD90]	[13]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Ropinirole when combined with Metoclopramide.	Nausea/vomiting [MD90]	[13]
Thiethylperazine	DMU3IET	Moderate	Antagonize the effect of Ropinirole when combined with Thiethylperazine.	Nausea/vomiting [MD90]	[13]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Ropinirole and Apraclonidine.	Optic nerve disorder [9C40]	[18]
Rofecoxib	DM3P5DA	Moderate	Decreased metabolism of Ropinirole caused by Rofecoxib mediated inhibition of CYP450 enzyme.	Osteoarthritis [FA00-FA05]	[14]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Ropinirole caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[17]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Ropinirole caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[26]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Ropinirole and Dextropropoxyphene.	Pain [MG30-MG3Z]	[27]
Thiabendazole	DM7YCK3	Moderate	Decreased metabolism of Ropinirole caused by Thiabendazole mediated inhibition of CYP450 enzyme.	Parasitic worm infestation [1F90]	[14]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Ropinirole caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[28]
Levomepromazine	DMIKFEL	Moderate	Antagonize the effect of Ropinirole when combined with Levomepromazine.	Psychotic disorder [6A20-6A25]	[13]
Fluphenazine	DMIT8LX	Moderate	Antagonize the effect of Ropinirole when combined with Fluphenazine.	Psychotic disorder [6A20-6A25]	[13]
Triflupromazine	DMKFQJP	Moderate	Antagonize the effect of Ropinirole when combined with Triflupromazine.	Psychotic disorder [6A20-6A25]	[13]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Ropinirole and Quetiapine.	Schizophrenia [6A20]	[13]
Mesoridazine	DM2ZGAN	Moderate	Antagonize the effect of Ropinirole when combined with Mesoridazine.	Schizophrenia [6A20]	[13]
Thioridazine	DM35M8J	Moderate	Antagonize the effect of Ropinirole when combined with Thioridazine.	Schizophrenia [6A20]	[13]
Aripiprazole	DM3NUMH	Moderate	Antagonize the effect of Ropinirole when combined with Aripiprazole.	Schizophrenia [6A20]	[13]
Iloperidone	DM6AUFY	Moderate	Antagonize the effect of Ropinirole when combined with Iloperidone.	Schizophrenia [6A20]	[13]
Paliperidone	DM7NPJS	Moderate	Antagonize the effect of Ropinirole when combined with Paliperidone.	Schizophrenia [6A20]	[13]
Loxapine	DM8AI9U	Moderate	Antagonize the effect of Ropinirole when combined with Loxapine.	Schizophrenia [6A20]	[13]
Haloperidol	DM96SE0	Moderate	Antagonize the effect of Ropinirole when combined with Haloperidol.	Schizophrenia [6A20]	[13]
Perphenazine	DMA4MRX	Moderate	Antagonize the effect of Ropinirole when combined with Perphenazine.	Schizophrenia [6A20]	[13]
Molindone	DMAH70G	Moderate	Antagonize the effect of Ropinirole when combined with Molindone.	Schizophrenia [6A20]	[13]
Chlorpromazine	DMBGZI3	Moderate	Antagonize the effect of Ropinirole when combined with Chlorpromazine.	Schizophrenia [6A20]	[13]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Ropinirole and Thiothixene.	Schizophrenia [6A20]	[13]
Clozapine	DMFC71L	Moderate	Antagonize the effect of Ropinirole when combined with Clozapine.	Schizophrenia [6A20]	[13]
Trifluoperazine	DMKBYWI	Moderate	Additive CNS depression effects by the combination of Ropinirole and Trifluoperazine.	Schizophrenia [6A20]	[13]
Risperidone	DMN6DXL	Moderate	Antagonize the effect of Ropinirole when combined with Risperidone.	Schizophrenia [6A20]	[13]
Olanzapine	DMPFN6Y	Moderate	Antagonize the effect of Ropinirole when combined with Olanzapine.	Schizophrenia [6A20]	[13]
Amisulpride	DMSJVAM	Major	Antagonize the effect of Ropinirole when combined with Amisulpride.	Schizophrenia [6A20]	[17]
Asenapine	DMSQZE2	Moderate	Antagonize the effect of Ropinirole when combined with Asenapine.	Schizophrenia [6A20]	[13]
Pimozide	DMW83TP	Moderate	Antagonize the effect of Ropinirole when combined with Pimozide.	Schizophrenia [6A20]	[13]
Warfarin	DMJYCVW	Moderate	Increased plasma concentration of Ropinirole and Warfarin due to competitive binding of plasma proteins.	Supraventricular tachyarrhythmia [BC81]	[29]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Ropinirole and Tizanidine.	Tonus and reflex abnormality [MB47]	[30]
Nalidixic acid	DMRM0JV	Moderate	Decreased metabolism of Ropinirole caused by Nalidixic acid mediated inhibition of CYP450 enzyme.	Urinary tract infection [GC08]	[14]
Enoxacin	DMYTE6L	Moderate	Decreased metabolism of Ropinirole caused by Enoxacin mediated inhibition of CYP450 enzyme.	Urinary tract infection [GC08]	[14]
Methdilazine	DMAUHQX	Moderate	Antagonize the effect of Ropinirole when combined with Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[13]
Trimeprazine	DMEMV9D	Moderate	Antagonize the effect of Ropinirole when combined with Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[31]
Cetirizine	DMOMP9U	Moderate	Additive CNS depression effects by the combination of Ropinirole and Cetirizine.	Vasomotor/allergic rhinitis [CA08]	[32]
Mexiletine	DMCTE9R	Moderate	Decreased metabolism of Ropinirole caused by Mexiletine mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[14]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Ropinirole caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[14]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Ropinirole caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[14]
-----------


⏷ Show the Full List of 71 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Caprylic acid	E00017	379	Emulsifying agent; Flavoring agent; Surfactant
Carminic acid	E00506	10255083	Colorant
D&C red no. 27	E00381	83511	Colorant
D&C red no. 30	E00456	3000709	Colorant
Diethyl phthalate	E00135	6781	Plasticizing agent; Solvent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium	E00625	Not Available	Disintegrant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Glyceryl behenate	E00481	5362585	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Glyceryl dibehenate	E00537	22477175	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 39 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ropinirole 12 mg tablet	12 mg	24 HR Extended Release Oral Tablet	Oral
Ropinirole 0.25 mg tablet	0.25 mg	Oral Tablet	Oral
Ropinirole 0.5 mg tablet	0.5 mg	Oral Tablet	Oral
Ropinirole 1 mg tablet	1 mg	Oral Tablet	Oral
Ropinirole 2 mg tablet	2 mg	Oral Tablet	Oral
Ropinirole 4 mg tablet	4 mg	Oral Tablet	Oral
Ropinirole 5 mg tablet	5 mg	Oral Tablet	Oral
Ropinirole 4 mg tablet	4 mg	24 HR Extended Release Oral Tablet	Oral
Ropinirole 6 mg tablet	6 mg	24 HR Extended Release Oral Tablet	Oral
Ropinirole 8 mg tablet	8 mg	24 HR Extended Release Oral Tablet	Oral
Ropinirole 3 mg tablet	3 mg	Oral Tablet	Oral
Ropinirole 2 mg tablet	2 mg	24 HR Extended Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7295).
2	FDA Approved Drug Products: OZEMPIC (semaglutide) injection, for subcutaneous use
3	BDDCS applied to over 900 drugs
4	Ahire D, Sinha S, Brock B, Iyer R, Mandlekar S, Subramanian M: Metabolite Identification, Reaction Phenotyping, and Retrospective Drug-Drug Interaction Predictions of 17-Deacetylnorgestimate, the Active Component of the Oral Contraceptive Norgestimate. Drug Metab Dispos. 2017 Jun;45(6):676-685. doi: 10.1124/dmd.116.073940. Epub 2017 Mar 10.
5	Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000 Oct;39(4):243-54. doi: 10.2165/00003088-200039040-00001.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9	In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos. 1997 Jul;25(7):840-4.
10	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
11	D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways. FEBS Lett. 2008 Mar 5;582(5):603-10. doi: 10.1016/j.febslet.2008.01.028. Epub 2008 Jan 31.
12	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
13	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
14	Product Information. Noroxin (norfloxacin). Merck & Co, Inc, West Point, PA.
15	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
16	Product Information. Naropin (ropivacaine). Astra USA, Westborough, MA.
17	Cerner Multum, Inc. "Australian Product Information.".
18	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
19	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
20	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
21	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
22	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
23	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
24	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
25	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
26	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
27	Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
28	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
29	Bair JD, Oppelt TF "Warfarin and ropinirole interaction." Ann Pharmacother 35 (2001): 1202-4. [PMID: 11675845]
30	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
31	Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.
32	Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.